Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis.
Adrenal Cortex Hormones
/ adverse effects
Adult
Aged
Betacoronavirus
/ drug effects
COVID-19
Coronavirus Infections
/ diagnosis
Disease Progression
Female
Host-Pathogen Interactions
Humans
Length of Stay
Lung
/ diagnostic imaging
Male
Middle Aged
Multidetector Computed Tomography
Pandemics
Pneumonia, Viral
/ diagnosis
Propensity Score
Retrospective Studies
Risk Assessment
Risk Factors
SARS-CoV-2
Time Factors
Treatment Outcome
Virus Shedding
Journal
Shock (Augusta, Ga.)
ISSN: 1540-0514
Titre abrégé: Shock
Pays: United States
ID NLM: 9421564
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
5
6
2020
medline:
29
10
2020
entrez:
5
6
2020
Statut:
ppublish
Résumé
The effects of corticosteroid treatment on non-severe COVID-19 pneumonia patients are unknown. To determine the impacts of adjuvant corticosteroid administrated to patients with non-severe COVID-19 pneumonia. A retrospective cohort study based on propensity score analysis was designed to explore the effects of corticosteroid on several clinical outcomes. One hundred thirty-two patients satisfied the inclusion criteria and 35 pairs were generated according to propensity score matching. Compared to non-corticosteroid group, the CT score on day 7 was significantly higher in corticosteroid group (8.6 (interquartile range [IQR], 2.8-11.5) versus 12.0 (IQR, 5.0-19.3), P = 0.046). In corticosteroid group, more patients progressed to severe cases (11.4% versus 2.9%, P = 0.353), hospital stay (23.5 days (IQR, 19-29 d) versus 20.2 days (IQR, 14-25.3 d), P = 0.079) and duration of viral shedding (20.3 days (IQR, 15.2-24.8 d) versus 19.4 days (IQR, 11.5-28.3 d), P = 0.669) were prolonged, while fever time (9.5 days (IQR, 6.5-12.2 d) versus 10.2 days (IQR, 6.8-14 d), P = 0.28) was shortened; however, all these data revealed no statistically significant differences. Corticosteroid might have a negative effect on lung injury recovery in non-severe COVID-19 pneumonia patients; however, the results of this study must be interpreted with caution because of confounding factors.
Sections du résumé
BACKGROUND AND OBJECTIVE
The effects of corticosteroid treatment on non-severe COVID-19 pneumonia patients are unknown. To determine the impacts of adjuvant corticosteroid administrated to patients with non-severe COVID-19 pneumonia.
METHOD
A retrospective cohort study based on propensity score analysis was designed to explore the effects of corticosteroid on several clinical outcomes.
RESULTS
One hundred thirty-two patients satisfied the inclusion criteria and 35 pairs were generated according to propensity score matching. Compared to non-corticosteroid group, the CT score on day 7 was significantly higher in corticosteroid group (8.6 (interquartile range [IQR], 2.8-11.5) versus 12.0 (IQR, 5.0-19.3), P = 0.046). In corticosteroid group, more patients progressed to severe cases (11.4% versus 2.9%, P = 0.353), hospital stay (23.5 days (IQR, 19-29 d) versus 20.2 days (IQR, 14-25.3 d), P = 0.079) and duration of viral shedding (20.3 days (IQR, 15.2-24.8 d) versus 19.4 days (IQR, 11.5-28.3 d), P = 0.669) were prolonged, while fever time (9.5 days (IQR, 6.5-12.2 d) versus 10.2 days (IQR, 6.8-14 d), P = 0.28) was shortened; however, all these data revealed no statistically significant differences.
CONCLUSION
Corticosteroid might have a negative effect on lung injury recovery in non-severe COVID-19 pneumonia patients; however, the results of this study must be interpreted with caution because of confounding factors.
Identifiants
pubmed: 32496422
doi: 10.1097/SHK.0000000000001574
pii: 00024382-202011000-00009
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
638-643Références
Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 23 (2):130–137, 2018.
WHO. Coronavirus. 2020; 2: 5. Available at: https://www.Who.Int/zh/emergencies/diseases/novel-coronavirus-2019. Accessed February 20, 2020.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (10223):497–506, 2020.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395 (10223):507–513, 2020.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al. Early transmission dynamics in wuhan, china, of novel coronavirus-infected pneumonia. N Engl J Med 382 (13):1199–1207, 2020.
WHO. Coronavirus disease 2019. Situation reports. 2020; 3: 15. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200316-sitrep-56-covid-19.pdf?sfvrsn=9fda7db2_2. Accessed March 29, 2020.
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395 (10223):473–475, 2020.
Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet V 395 2020; (10225):683–684.
Zhao JP, Hu Y, Du RH, Chen ZS, Jin Y, Zhou M, Zhang J, Qu JM, Cao B. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi 43 (3):183–184, 2020.
Global surveillance for human infection with novel coronavirus (2019-ncov) interim guidance v3. 2020; 1: 31. Available at: Https://www.Who.Int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov). Accessed February 10, 2020.
Feng F, Jiang Y, Yuan M, Shen J, Yin H, Geng D, Xu J, Hua Y, Shi J, Shi Y, et al. Association of radiologic findings with mortality in patients with avian influenza H7N9 pneumonia. PLoS One 9 (4):e93885, 2014.
Yuan M, Yin W, Tao Z, Tan W, Hu Y. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS One 15 (3):e0230548, 2020.
Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med 372 (13):1213–1222, 2015.
WHO. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. 2020; 3:13. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020; e200994.
Arabi YM, Balkhy HH, Hayden FG, Bouchama A, Luke T, Baillie JK, Al-Omari A, Hajeer AH, Senga M, Denison MR, et al. Middle east respiratory syndrome. N Engl J Med 376 (6):584–594, 2017.
Beijing Group of National Research Project for SARS. Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome. Chin Med J (Engl) 116 (9):1283–1287, 2003.
Zhou Y, Fu X, Liu X, Huang C, Tian G, Ding C, Wu J, Lan L, Yang S. Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis. Sci Rep 10 (1):3044, 2020.
Li H, Yang SG, Gu L, Zhang Y, Yan XX, Liang ZA, Zhang W, Jia HY, Chen W, Liu M, et al. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. Influenza Other Respir Viruses 11 (4):345–354, 2017.
Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 3 (9):e343, 2006.
Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, Zhong N. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest 129 (6):1441–1452, 2006.
Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, Jose J, Pinto R, Al-Omari A, Kharaba A, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med 197 (6):757–767, 2018.
Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, Dong N, Tong Q. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. MedRxiv 2020.
Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, Chiu RW, Wong VW, Chan PK, Wong KT, Wong E, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 31 (4):304–309, 2004.
Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med 382:1653–1659, 2020.
Mendelsohn FA, Lloyd CJ, Kachel C, Funder JW. Induction by glucocorticoids of angiotensin converting enzyme production from bovine endothelial cells in culture and rat lung in vivo. J Clin Invest 70:684–692, 1982.
Ullian ME. The role of corticosteroids in the regulation of vascular tone. Cardiovasc Res 41:55–64, 1999.
Fang X, Mei Q, Yang T, Li L, Wang Y, Tong F, Geng S, Pan A. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J Infect 81 (1):147–178, 2020.
Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 382 (12):1177–1179, 2020.